Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide for Oral Intraepithelial Neoplasia
NCT00003223Phase 2Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Dec 1997
- Primary completion
- Mar 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fenretinide in Oral intraepithelial neoplasia (OIN), sponsored by SWOG Cancer Research Network. Primary endpoint: Efficacy (Histologic Response) at 6 months. Started Dec 1997; status: terminated.
02
Drugs
fenretinide
03
Conditions
Oral intraepithelial neoplasia (OIN)
Beyond the preview
Go deeper on NCT00003223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003223.